NeoGenomics, Inc.

NasdaqCM:NEO Stock Report

Market Cap: US$2.1b

NeoGenomics Management

Management criteria checks 3/4

NeoGenomics' CEO is Chris Smith, appointed in Aug 2022, has a tenure of 2.33 years. total yearly compensation is $11.67M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.5% of the company’s shares, worth $10.61M. The average tenure of the management team and the board of directors is 2.1 years and 3.9 years respectively.

Key information

Chris Smith

Chief executive officer

US$11.7m

Total compensation

CEO salary percentage8.6%
CEO tenure2.3yrs
CEO ownership0.5%
Management average tenure2.1yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Dec 26
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Aug 23
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16
Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10
We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11
Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07
Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

NeoGenomics: Gambling On Growth

Dec 16

CEO Compensation Analysis

How has Chris Smith's remuneration changed compared to NeoGenomics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$78m

Jun 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$84m

Dec 31 2023US$12mUS$1m

-US$88m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$126m

Dec 31 2022US$15mUS$346k

-US$144m

Compensation vs Market: Chris's total compensation ($USD11.67M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Smith (61 yo)

2.3yrs

Tenure

US$11,665,946

Compensation

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Smith
CEO & Director2.3yrsUS$11.67m0.50%
$ 10.6m
Jeffrey Sherman
Chief Financial Officer2yrsUS$3.55m0.096%
$ 2.0m
Vishal Sikri
President of Advanced Diagnostics2.9yrsUS$2.37m0.10%
$ 2.1m
Melody Harris
President & COO of Informatics2yrsUS$4.69m0.084%
$ 1.8m
Warren Stone
Chief Commercial Officer2.1yrsUS$3.01m0.066%
$ 1.4m
Gregory Aunan
Chief Accounting Officer1.6yrsno data0.011%
$ 237.2k
Kendra Sweeney
Vice President of Investor Relations & Communicationsno datano datano data
Alicia Olivo
Executive VP of Business Development2.7yrsno data0.029%
$ 609.4k
Hutan Hashemi
Chief Compliance Officer2.7yrsno datano data
Derek Lyle
Chief Medical Officer3.9yrsno datano data
Gary Passman
Chief Culture Officer1.9yrsno datano data
Kareem Saad
Head of Strategy & Transformationless than a yearno datano data

2.1yrs

Average Tenure

51yo

Average Age

Experienced Management: NEO's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Smith
CEO & Director2.3yrsUS$11.67m0.50%
$ 10.6m
Michael Kelly
Independent Director4.4yrsUS$317.50k0.025%
$ 521.1k
Lynn Tetrault
Independent Chair of the Board9.5yrsUS$365.00k0.048%
$ 1.0m
Bernard Fox
Member of Scientific Advisory Board3.9yrsno datano data
Riccardo Dalla-Favera
Member of Scientific Advisory Board3.9yrsno datano data
Anthony Zook
Independent Director1.5yrsUS$276.23k0.0088%
$ 186.0k
Steven Rosen
Member of Scientific Advisory Board3.9yrsno datano data
James Downing
Member of Scientific Advisory Board3.9yrsno datano data
Stephen Kanovsky
Independent Director7.4yrsUS$309.20k0.028%
$ 592.3k
Razelle Kurzrock
Member of Scientific Advisory Board3.9yrsno datano data
Alison Hannah
Member of Scientific Advisory Board & Independent Director9.5yrsUS$305.00k0.093%
$ 1.9m
Mark Rubin
Member of Scientific Advisory Board3.9yrsno datano data

3.9yrs

Average Tenure

63yo

Average Age

Experienced Board: NEO's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeoGenomics, Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Raymond MyersBenchmark Company
Derik de BruinBofA Global Research